Disclosures for "EMERALD: A Phase 3, Randomized, Multi-center, Double-blind, Placebo-controlled Clinical Trial to Evaluate the Efficacy, Safety, Tolerability, and Pharmacokinetics of Relutrigine in Participants with Developmental and Epileptic Encephalopathies"
-
Dr. Kamireddy has received personal compensation for serving as an employee of Praxis Precision Medicines. Dr. Kamireddy has stock in Praxis Precision Medicines.
-
Mr. Spar has received personal compensation for serving as an employee of Praxis Precision Medicines.
-
Kelley Dalby has received personal compensation for serving as an employee of Praxis Precision Medicines. Kelley Dalby has stock in Praxis Precision Medicines. Kelley Dalby has stock in RogCon.
-
Dr. Petrou has received personal compensation for serving as an employee of Praxis Precision Medicines. Dr. Petrou has stock in Praxis Precision Medicines. The institution of Dr. Petrou has received research support from Praxis Precision Medicines. Dr. Petrou has received intellectual property interests from a discovery or technology relating to health care.
-
Marcio Souza has received personal compensation for serving as an employee of Praxis Precision Medicines.